Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1330
Eli Lilly and Company
Eli Lilly and Company LLY | 0.00 |
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:
LLY) with a Overweight and raises the price target from $1280 to $1330.
